Lantern Pharma Inc.

LTRN · United States

Share price · LTRN

$0.33-2.19 (-86.93%) 3M

close as of 2026-11-18 · 24h delayed · vol 308K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LTRN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026-22.7%
  2. 28 Oct 2026+20.9%
  3. 2 Oct 2026-14.0%
  4. 28 Sep 2026-10.7%
  5. 24 Sep 2026-12.9%
  6. 22 Sep 2026-9.3%
  7. 17 Sep 2026-11.4%
  8. 16 Sep 2026+13.5%
  9. 14 May 2026+24.7%
  10. 13 May 2026+21.8%

Share of unusual movement by asset

For each asset, the share of LTRN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Dimesna
events and moves
2shown from 8 days
Zirdafulven
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—84%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
EGFR / ALK / MET / ROS1 (via extracellular disulfide-bond disruption) plus thioredoxin/glutaredoxin/peroxiredoxinSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
PTGR1 (Prostaglandin Reductase 1, bioactivating enzyme)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
DimesnaPhase 2Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
Est. primary completion 2026-12 · NCT05456256 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026Topline resultDimesnaLP-300 Phase 3 trials failed to meet endpoints

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$1.8M$6.7M+ $0.7M short-term inv.$7.1M-$2.9M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$1.7M$4.9M+ $1.4M short-term inv.$3.3M-$3.8M operating cash flowreport ↗
2025-Q3—$2.4M$8.4M+ $4.0M short-term inv.$4.2M-$4.6M operating cash flowreport ↗
2025-Q2—$3.1M$6.1M+ $9.8M short-term inv.$4.3M-$3.9M operating cash flowreport ↗
2025-Q1—$3.3M$6.4M+ $13M short-term inv.$4.5M-$4.4M operating cash flowreport ↗
2024-Q3—$3.7M$8.1M+ $20M short-term inv.$4.5M-$5.6M operating cash flowreport ↗
2024-Q2—$3.9M$13M+ $20M short-term inv.$5.0M-$5.2M operating cash flowreport ↗
2024-Q1—$4.3M$18M+ $20M short-term inv.$5.4M-$3.1M operating cash flowreport ↗
2023-Q3—$2.2M$26M+ $19M short-term inv.$3.2M-$3.6M operating cash flowreport ↗
2023-Q2—$3.6M$28M+ $20M short-term inv.$4.8M-$3.6M operating cash flowreport ↗
2023-Q1—$2.5M$32M+ $19M short-term inv.$3.9M-$3.8M operating cash flowreport ↗
2022-Q3—$0.7M$39M+ $19M short-term inv.$2.3M-$4.0M operating cash flowreport ↗
2022-Q2—$3.0M$43M+ $19M short-term inv.$4.5M-$2.7M operating cash flowreport ↗
2022-Q1—$2.7M$47M+ $19M short-term inv.$4.1M-$3.3M operating cash flowreport ↗
2021-Q3—$3.0M$55M+ $19M short-term inv.$4.0M-$4.7M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$12M$4.4M+ $5.7M short-term inv.$4.3M-$16M operating cash flowreport ↗

Lantern Pharma did not disclose revenue for FY2025. R&D expense was $11.51M, down 28.6% YoY, and cash and equivalents were $4.42M at year-end, with a full-year net loss of $17.12M and quarterly net burn of $17.12M. Management also reported approximately $10.1M in cash, cash equivalents, and marketable securities.

Management guided that existing cash would fund operations until at least late July 2026 to mid-September 2026 and noted that substantial additional funding will be required. Clinical progress included continued LP-300 HARMONIC trial enrollment with an FDA Type C meeting scheduled for mid-May 2026, LP-184 Phase 1a completion with a 48% clinical benefit rate and planned biomarker-guided Phase 1b/2 trials, FDA IND clearance for Starlight Therapeutics’ STAR-001 pediatric CNS cancer trial, and LP-284 Orphan Drug Designation for soft tissue sarcomas. The company also advanced its RADR AI platform and introduced withZeta.ai, which entered beta testing with over 25 organizations.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$16M$7.5M+ $17M short-term inv.$5.2M-$18M operating cash flowreport ↗
2023-FY—$12M$22M+ $19M short-term inv.$4.0M-$14M operating cash flowreport ↗
2022-FY—$8.6M$37M+ $18M short-term inv.$3.6M-$13M operating cash flowreport ↗
2021-FY—$7.6M$52M+ $19M short-term inv.$3.1M-$11M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($200K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-05-12KEYSER D JEFFREY · directorOpen-market purchase48,544$2.06$100KForm 4
2026-05-12Schalop Lee Troy · directorOpen-market purchase48,544$2.06$100KForm 4
2026-05-12KEYSER D JEFFREY · directorOpen-market purchase (derivative)48,544$0.00$0Form 4
2026-05-12Schalop Lee Troy · directorOpen-market purchase (derivative)48,544$0.00$0Form 4
2026-01-09Silberstein David S. · directorAward / grant (derivative)25,000——Form 4
2026-01-09Schalop Lee Troy · directorAward / grant (derivative)25,000——Form 4
2026-01-09Chandru Vijay · directorAward / grant (derivative)25,000——Form 4
2026-01-09Maccecchini Maria-Luisa · directorAward / grant (derivative)25,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 2.1M shares ($2.8M, 14.5% of shares outstanding).

#InstitutionSharesValue
1BIOS Capital Management, LP864,435$1.2M
2VANGUARD CAPITAL MANAGEMENT LLC332,079$455K
3CM Management, LLC250,000$343K
4RENAISSANCE TECHNOLOGIES LLC116,000$159K
5GEODE CAPITAL MANAGEMENT, LLC111,646$153K
6Westside Investment Management, Inc.50,050$69K
7Voss Capital, LP50,000$69K
8VANGUARD FIDUCIARY TRUST CO49,607$68K
9BlackRock, Inc.45,267$62K
10DIMENSIONAL FUND ADVISORS LP38,060$52K
11HORIZON KINETICS ASSET MANAGEMENT LLC26,373$36K
12DAVENPORT & Co LLC23,814$33K
13STATE STREET CORP23,652$32K
14Bank of New York Mellon Corp21,301$29K
15NORTHERN TRUST CORP15,589$21K